Ocular adverse events of molecularly targeted agents approved in solid tumours: A systematic review
| Autor: | Christophe Le Tourneau, Simona Pop, Livia Lumbroso-Le Rouic, Olivier Huillard, Christine Levy, Marie-Paule Sablin, Laurence Desjardins, Silvin Bakalian |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Cancer Research
medicine.medical_specialty Chemotherapy Dose limiting toxicity Eye Diseases business.industry medicine.medical_treatment Antineoplastic Agents macromolecular substances Surgery Ocular toxicity Clinical trial Treatment Outcome Oncology Dose-Limiting Neoplasms Daily practice medicine Humans Severe pain Molecular Targeted Therapy Adverse effect business Intensive care medicine |
| Zdroj: | European Journal of Cancer. 50:638-648 |
| ISSN: | 0959-8049 |
| Popis: | When using molecularly targeted agents (MTAs), oncologists and patients face new and sometimes unexpected toxicities. Though ocular adverse events (OAEs) are not uncommon with chemotherapy, they are rarely severe or dose limiting. Ocular toxicity profile may differ with MTAs, indeed severe and dose limiting toxicities have been described with targeted therapies currently under investigation. Our study aimed to review OAEs experienced with MTAs approved in solid tumours. This review revealed that many OAEs, frequent and potentially severe, exist and concern most MTAs. The suggestion is prompt referral of patients with severe pain and/or visual impairment to the ophthalmologist since these symptoms can be associated with potentially severe OAE and need ophthalmic assessment. Oncologists must be aware of such events and their potential severity for better treatment and better diagnosis in daily practice as well as in clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect